Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia
Diseases of the Kidney & Urinary Tract
What is the purpose of this trial?
Phase 2, multi-center, open label, single arm study to evaluate the effect and safety of ALLN-177 in adult and pediatric patients aged 12 and older with enteric hyperoxaluria and hyperoxalemia or primary hyperoxaluria .
Approximately 15-20 evaluable subjects are planned to be enrolled in the study. Eligible subjects will administer ALLN-177 with each meal/snack 5 times per day for 12 consecutive weeks.
- Ages12 years and older
- Trial withAllena Pharmaceuticals, Inc.
- Start Date07/17/2018
- End Date06/29/2019
- Last Updated09/11/2018
- Study HIC#2000022913